Paper39724461
The influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment.
Mahmoudian F and 4 others. Mol Biol Rep, 2024. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. The influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment. Papers, record 39724461. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39724461
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Dysbiosis | Major topic |
| Gastrointestinal Microbiome | Major topic |
| Immunotherapy | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Humans | |
| Fecal Microbiota Transplantation |
Source PubMed
References84
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33303685 | Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. | Science | 2021 | https://conductscience.org/library/papers/33303685 | PubMed |
| 2 | 36143126 | Composition of the Gut Microbiota Associated with the Response to Immunotherapy in Advanced Cancer Patients: A Chinese Real-World Pilot Study. | J Clin Med | 2022 | https://conductscience.org/library/papers/36143126 | PubMed |
| 3 | 37602831 | Faecalibacterium prausnitzii Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade. | Cancer Res | 2023 | https://conductscience.org/library/papers/37602831 | PubMed |
| 4 | 37179402 | Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37179402 | PubMed |
| 5 | 32376136 | Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. | Eur Urol | 2020 | https://conductscience.org/library/papers/32376136 | PubMed |
| 6 | 36134612 | Probiotic immunonutrition impacts on colon cancer immunotherapy and prevention. | Eur J Cancer Prev | 2023 | https://conductscience.org/library/papers/36134612 | PubMed |
| 7 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 8 | 38870711 | Cause and consequence of heterogeneity in human mesenchymal stem cells: Challenges in clinical application. | Pathol Res Pract | 2024 | https://conductscience.org/library/papers/38870711 | PubMed |
| 9 | 39141261 | Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis. | Invest New Drugs | 2024 | https://conductscience.org/library/papers/39141261 | PubMed |
| 10 | 36339577 | Untargeted metabolomics analysis of the hippocampus and cerebral cortex identified the neuroprotective mechanisms of Bushen Tiansui formula in an aβ25-35-induced rat model of Alzheimer's disease. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36339577 | PubMed |
| 11 | 38840029 | Exploiting bacteria for cancer immunotherapy. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/38840029 | PubMed |
| 12 | 36309208 | Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy. | Gastroenterology | 2023 | https://conductscience.org/library/papers/36309208 | PubMed |
| 13 | 37227176 | Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. | Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37227176 | PubMed |
| 14 | 36003049 | Dermatophagoides pteronyssinus allergen Der p 22: Cloning, expression, IgE-binding in asthmatic children, and immunogenicity. | Pediatr Allergy Immunol | 2022 | https://conductscience.org/library/papers/36003049 | PubMed |
| 15 | 34873013 | Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34873013 | PubMed |
| 16 | 34200997 | The Evolution of Cancer Immunotherapy. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/34200997 | PubMed |
| 17 | 29255057 | Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/29255057 | PubMed |
| 18 | 31564086 | Optimal body mass index for minimizing the risk for osteoporosis and type 2 diabetes. | Korean J Intern Med | 2020 | https://conductscience.org/library/papers/31564086 | PubMed |
| 19 | 37465523 | Effects of Litsea cubeba essential oil on growth performance, blood antioxidation, immune function, apparent digestibility of nutrients, and fecal microflora of pigs. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37465523 | PubMed |
| 20 | 38035338 | Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer. | Front Cell Infect Microbiol | 2023 | https://conductscience.org/library/papers/38035338 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41597216 | VERU-111 Promotes an Anti-Tumor Response Through Restoration of Gut Microbial Homeostasis and Associated Metabolic Dysregulation. | Cells | 2026 | https://conductscience.org/library/papers/41597216 | PubMed |
| 41300985 | Microbiota and Pancreatic Cancer: New Therapeutic Frontiers Between Engineered Microbes, Metabolites and Non-Bacterial Components. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41300985 | PubMed |
| 41186720 | The gut-brain axis: role of gut microbiota in neurological disease pathogenesis and pharmacotherapeutics. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41186720 | PubMed |
| 40927726 | Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments. | Front Immunol | 2025 | https://conductscience.org/library/papers/40927726 | PubMed |
| 40564016 | The Microbiome Connection: A Common Pathway Linking Cancer and Heart Failure. | Biomedicines | 2025 | https://conductscience.org/library/papers/40564016 | PubMed |
| 40406094 | Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome profiling. | Front Immunol | 2025 | https://conductscience.org/library/papers/40406094 | PubMed |
| 40136508 | The Gut Microbiota and Colorectal Cancer: Understanding the Link and Exploring Therapeutic Interventions. | Biology (Basel) | 2025 | https://conductscience.org/library/papers/40136508 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39724461
GET https://conductscience.org/api/papers/v1/39724461/references?page=2